Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
2.
Work ; 57(4): 469-473, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28777764

RESUMO

Telehealth approaches to delivering ergonomics assessment hold great potential to improve service delivery in rural and remote settings. This case study describes a telehealth-based ergonomics service delivery process, and compares in-person and telehealth-based ergonomics approaches at an Alberta-based non-profit advocacy group. This project demonstrates that telehealth approaches to ergonomics do not lead to significantly different scoring outcomes for assessment of ergonomics issues, when compared to in-person assessments. This project also outlines the importance of live real-time video conferencing to improving communication, attaining key assessment information, and demonstrating ergonomic adjustments. However, some key considerations of bandwidth and hardware capabilities need to be taken into account. Key communication strategies are outlined to improve rapport, maintain employee confidentiality, and reduce client anxiety around telehealth ergonomics assessments. This project provides further support for telehealth approaches to office ergonomics, and outlines some key implementation strategies and barriers that should be considered.


Assuntos
Ergonomia/métodos , Decoração de Interiores e Mobiliário/normas , Telemedicina/estatística & dados numéricos , Adulto , Alberta , Computadores/normas , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Organizações sem Fins Lucrativos , Telemedicina/métodos , Comunicação por Videoconferência , Local de Trabalho
3.
ACS Med Chem Lett ; 8(5): 582-586, 2017 May 11.
Artigo em Inglês | MEDLINE | ID: mdl-28523115

RESUMO

Further optimization of an initial DP2 receptor antagonist clinical candidate NVP-QAV680 led to the discovery of a follow-up molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid (compound 11, NVP-QAW039, fevipiprant), which exhibits improved potency on human eosinophils and Th2 cells, together with a longer receptor residence time, and is currently in clinical trials for severe asthma.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA